Background: Screening biomarkers for ovarian cancer are needed because of its late stage at diagnosis and poor survival. We used microarray technology to identify overexpressed genes for secretory proteins as potential serum biomarkers and selected prostasin, a serine protease normally secreted by the prostate gland, for further study. Methods: RNA was isolated and pooled from three ovarian cancer cell lines and from three normal human ovarian surface epithelial (HOSE) cell lines. Complementary DNA generated from these pools was hybridized to a microarray slide, and genes overexpressed in the cancer cells were identified. Real-time quantitative polymerase chain reaction was used to examine prostasin gene expression in ovarian cancer and HOSE cell lines. Anti-prostasin antibodies were used to examine prostasin expression and to measure serum prostasin by an enzyme-linked immunosorbent assay in 64 case patients with ovarian cancer and in 137 control subjects. Previously determined levels of CA 125, an ovarian cancer marker, were available from about 70% of all subjects. All statistical tests were two-sided. Results: Prostasin was detected by immunostaining more strongly in cancerous ovarian epithelial cells and stroma than in normal ovarian tissue. The mean level of serum prostasin was 13.7 µg/mL (95% confidence interval [CI] = 10.5 to 16.9 µg/mL) in 64 case patients with ovarian cancer and 7.5 µg/mL (95% CI = 6.6 to 8.3 µg/mL) in 137 control subjects (P<.001, after adjustment for the subject's age, year of collection, and specimen quality). In 14 of 16 case patients with both preoperative and postoperative serum samples, postoperative prostasin levels were statistically significantly lower than preoperative levels (P = .004). In 37 case patients with nonmucinous ovarian cancer and in 100 control subjects for whom levels of CA 125 and prostasin were available, the combination of markers gave a sensitivity of 92% (95% CI = 78.1% to 98.3%) and a specificity of 94% (95% CI = 87.4% to 97.7%) for detecting ovarian cancer. 
Ovarian cancer ranks closely behind pancreatic cancer as the fifth leading cause of death from cancer in U.S. women and is the most lethal of the gynecologic cancers (1) . The majority of women with ovarian cancer are diagnosed when they have distant disease, and the proportion surviving after 5 years is around 28% (2) . Alternatively, for the minority of women diagnosed with the disease confined to the ovaries, the proportion surviving after 5 years is about 90% (depending on the tumor grade). Thus, ovarian cancer is an obvious target for better approaches to early detection, including the identification of appropriate molecular markers.
Microarray technology permits the simultaneous comparison of the expression of thousands of genes in samples to allow identification of those that are differentially expressed. The technique has been applied to the molecular classification of tumors (3) (4) (5) and may also be able to identify overexpressed complementary DNA (cDNA) corresponding to secretory proteins that might serve as serum markers for cancer. In this article, we describe the application of microarray technology to identify novel molecular markers for ovarian cancer and explore the potential clinical value of one of the candidate markers (called prostasin) thus identified.
MATERIALS AND METHODS

Biologic Specimens
All patient-derived biologic specimens were collected and archived under protocols approved by the Human Subjects Committee of the Brigham and Women's Hospital, Boston, MA, or were approved for study under guidelines covering discarded human materials. Ovarian tissue and cells were freshly collected from women undergoing surgery at the Brigham and Women's Hospital for a diagnosis of primary ovarian cancer or from control subjects having hysterectomy and oophorectomy for benign disease. Cultures of normal human ovarian surface epithelial (HOSE) cells were established by scraping the surface of the ovary and growing recovered cells in a mixture of medium 199 and MCDB105 medium supplemented with 10% fetal calf serum (Sigma Chemical Co., St. Louis, MO) as described previously (6) . The following seven normal HOSE cells were used: HOSE17, HOSE636, HOSE642, HOSE697, HOSE713, HOSE726, and HOSE730. Ovarian cancer cell lines were established by recovery from ascites fluid or explanted from solid tumors as described previously (6) . The following 10 ovarian cancer cell lines were used: OVCA3, OVCA420, OVCA429, OVCA432, OVCA433, OVCA633, CAOV3, DOV13, ALST, and SKOV3. All of the cell cultures and cell lines were established in the Laboratory of Gynecologic Oncology, Brigham and Woman's Hospital, with the exception of SKOV3, which was purchased from the American Type Culture Collection, Manassas, VA. RNA was extracted from individual or pooled cell lines by using a micro RNA extraction kit as described by the manufacturer (Qiagen, Valencia, CA) and quantified by fluorometry (Gemini Bio-Products, Inc., Calabasas, VA).
Serum specimens from women with ovarian cancer, other gynecologic cancers, and benign gynecologic disorders requiring hysterectomy and from nondiseased normal women were obtained from discarded specimens and from discarded specimens that were archived during the period from 1983 through 1988 or from specimens collected under more recent protocols since 1996. The archived samples were collected from several studies, from 1983 through 1988, assessing the performance of CA 125 in a variety of diagnostic circumstances, including gynecologically normal subjects as well as subjects having exploratory surgery for pelvic masses that proved to be ovarian, cervical, or endometrial cancer or a benign disease such as fibroid tumors (7) (8) (9) . These archived specimens were stored at −70°C. However, during relocation of the Laboratory of Gynecologic Oncology, thawing was known to have occurred once for some of the archived specimens. Archived specimens that had been obtained preoperatively from the case patients and from the surgical control subjects were identified and recovered. The recently collected specimens are those being obtained with written informed consent as part of ongoing studies of ovarian cancer sponsored by the Obstetrics/Gynecology Epidemiology Unit and the Laboratory of Gynecologic Oncology, Brigham and Women's Hospital. These specimens were obtained within the past 5 years and were stored at −70°C without any incident of thawing. In both specimen banks, serum from case patients with ovarian cancer and serum from control patients were collected concurrently.
Microarray Probe and Hybridization
The MICROMAX™ human cDNA microarray system I (NEN Life Science Products, Inc., Boston, MA), which contains 2400 known human cDNA on a slide 1 inch × 3 inches, was used in this study. Biotin-labeled cDNA was generated from 3 g of total RNA that was pooled from HOSE17, HOSE636, and HOSE642 cells. Dinitrophenyl-labeled cDNA was generated from 3 g of total RNA that was pooled from ovarian cancer cell lines OVCA420, OVCA433, and SKOV3. Before the cDNA reaction, equal amounts (5 ng) of Arabidopsis control RNA were added to each batch of the RNA samples for the normalization of hybridization signals. The biotin-labeled cDNA and the dinitrophenyl-labeled cDNA were mixed, dried, and resuspended in 20 L of hybridization buffer (5× standard saline citrate [SSC], 0.1% sodium dodecyl sulfate [SDS] , and salmon sperm DNA at 0.1 mg/mL [1× SSC ‫ס‬ 0.15 M NaCl-0.15 M sodium citrate, pH 7] ). This mixture was added to the cDNA microarray and was covered with a coverslip. Hybridization was carried out overnight at 65°C inside a hybridization cassette (Telechem, Inc., Sunnyvale, CA).
After hybridization, the microarray was washed with 30 mL of 0.5× SSC-0.01% SDS, with 30 mL of 0.06× SSC-0.01% SDS, and then with 30 mL of 0.06× SSC alone. The hybridization signal from biotin-labeled cDNA was amplified with streptavidin-horseradish peroxidase and a fluorescent dye, Cy5™-tyramide (NEN Life Science Products, Inc.), and the hybridization signal from the dinitrophenyl-labeled cDNA was amplified with anti-dinitrophenylhorseradish peroxidase and another fluorescent dye, Cy3™-tyramide (NEN Life Science Products, Inc.). After signal amplification and a posthybridization wash in TNT buffer (i.e., 0.1 M Tris-HCl [pH 7.5]-0.15 M NaCl-0.15% Tween 20), the microarray was air-dried, and signal amplification was detected with a laser scanner.
Laser detection of the Cy3 signal (derived from ovarian cancer cells) and the Cy5 signal (derived from HOSE cells) on the microarray was acquired with a confocal laser reader, ScanArray3000 (GSI Lumonics, Watertown, MA). Separate scans were taken for each fluor at a pixel size of 10 m. cDNA derived from the added Arabidopsis RNA hybridized to 12 specific spots on the microarray, which were composed of DNA sequences obtained from four different Arabidopsis, expressed sequence tags in triplicate (NEN Life Science Products, Inc.). Cy3 and Cy5 signals from these 12 spots should theoretically be equal and were used to normalize the different efficiencies in labeling and detection with the two fluors. The fluorescence signal intensity and the ratio of the signals from Cy3 and Cy5 for each of the 2400 cDNAs were analyzed by the software Imagene 3.0 (Biodiscovery Inc., Los Angeles, CA).
Real-Time Quantitative Reverse Transcription-Polymerase Chain Reaction
Real-time reverse transcription-polymerase chain reaction (RT-PCR) was performed in duplicate by using primer sets specific for the overexpressed gene encoding the secretory protein called prostasin (forward primer ‫ס‬ 5Ј-ACTTGAGCCACTCCTTCCTTCAG-3Ј; reverse primer ‫ס‬ 5Ј-CTGATGGTC-CCAAAAAGCACAC-3Ј) and a housekeeping gene, GADPH, in an ABI PRISM 5700 Sequence Detector (PE Applied Biosystems, Foster City, CA). RNA was first extracted from normal ovarian epithelial cell cultures (HOSE697, HOSE713, HOSE726, and HOSE730) and from 10 ovarian carcinoma cell lines (OVCA3, OVCA420, OVCA429, OVCA432, OVCA433, OVCA633, CAOV3, DOV13, SKOV3, and ALST). cDNA was generated from 1 g of total RNA by using the TaqMan RT reagents containing 1× TaqMan reverse transcriptase buffer, 5.5 mM MgCl 2 , all four deoxyribonucleoside triphosphates (each at 500 M), 2.5 M random hexamer, MultiScribe reverse transcriptase (PE Applied Biosystems) at 1.25 U/L, and RNasin (Promega Corp., Madison, WI) at 0.4 U/L in 100 L. The reaction was incubated at 25°C for 10 minutes, at 48°C for 30 minutes, and finally at 95°C for 5 minutes. A total of 1 g of cDNA was used in a 20-L PCR mixture containing 1× SYBR® PCR buffer, 3 mM MgCl 2 , all four deoxyribonucleoside triphosphates (each at 0.8 mM), and AmpliTaq Gold (all from PE Applied Biosystems). The cDNAs were then amplified by denaturation for 10 minutes at 95°C, followed by 40 PCR cycles of denaturation at 95°C for 15 seconds and annealing-extension at 60°C for 1 minute. The changes in fluorescence of the SYBR Green I dye in every cycle were monitored by ABI5700 system software, and the threshold cycle (C T ), which represents the PCR cycle at which an increase in reporter fluorescence above a baseline signal can first be detected for each reaction, was calculated as described by Heid et al. (10) . The relative amount of PCR products generated from each primer set was determined on the basis of the C T value. GAPDH was used to normalize the quantity of RNA used. Its C T value was then subtracted from that of each target gene to obtain a ⌬C T value. The difference (⌬⌬C T ) between the ⌬C T values of the samples for each gene target and the ⌬C T value of a calibrator (sample 697), which served as a physiologic reference, was determined. The relative quantitative value was expressed as 2 −⌬⌬CT . For confirmation of the specificity of the PCR, PCR products were subjected to electrophoresis on a 1.2% agarose gel. A single PCR product with the expected size should be observed in samples that express the gene of interest.
Immunohistochemical Localization of Prostasin
Immunostaining with an anti-prostasin antibody was performed on sections prepared from two normal ovaries, from two serous borderline ovarian tumors, and from two grade 1, two grade 2, and two grade 3 serous ovarian cystadenocarcinomas. This rabbit polyclonal antibody (provided by Dr. Julie Chao's laboratory) also used in the serum assay was prepared from prostasin purified from human seminal fluid as described previously (11) . Tissues were fixed in 4% paraformaldehyde and embedded in paraffin. Sections (5 m) were cut, mounted on Superfrost/Plus microscopic slides (Fisher Scientific, Pittsburgh, PA), and incubated at 50°C overnight. They were then transferred to Tris-buffered saline (TBS) and quenched in 0.2% H 2 O 2 for 20 minutes. After quenching, the sections were washed in TBS for 20 minutes, incubated with normal horse serum for 20 minutes, and then incubated with anti-prostasin polyclonal antibody (diluted 1 : 400) at room temperature for 1 hour. The slides were then washed in TBS for 10 minutes, incubated with diluted biotinylated secondary horse anti-rabbit antibody solution for 30 minutes, washed again in TBS for 10 minutes, incubated with avidin-biotin complex reagent (Vector Laboratories, Inc., Burlingame, CA) for 30 minutes, and washed in TBS for 10 minutes. Stain development was performed for 5 minutes by use of the diaminobenzidine kit (Vector Laboratories, Inc.). Finally, the sections were washed in water for 10 minutes. They were then counterstained with hematoxylin, dehydrated with an ascending series of alcohol solutions, cleared in xylene, and mounted in Permount (Fisher Scientific). The specificity of the staining was confirmed by using preimmunization rabbit serum and by preabsorbing the antibody with the purified peptide (60 mg/mL; Genosys, Woodlands, TX) or prostasin for 2 hours at 37°C before applying the adsorbed antiserum to the sections.
(IgG) (1 g/mL, 100 L per well) overnight at 4°C. Purified prostasin standards (0.16-10 ng) or samples were added to individual wells in a total volume of 100 L of phosphate-buffered saline containing 0.05% Tween 20 and 0.5% gelatin (dilution buffer) and incubated at 37°C for 90 minutes. Biotin-labeled antihuman prostasin IgG was added in each well at a concentration of 1 g/mL in a total of 100 L and incubated at 37°C for 60 minutes. Peroxidase-avidin at a concentration of 1 L/mL in a total volume of 100 L was added and incubated at 37°C for 30 minutes. The color reaction was performed by adding to each well 100 L of freshly prepared substrate solution [0.03% 2,2Ј-azino-bis(3-ethylbenzthiazoline-6-sulfonic acid) and 0.03% H 2 O 2 in 0.1 M sodium citrate (pH 4.3)] and incubating the mixture at room temperature for 30 minutes. The plates were read at 405 nm with a plate reader (Titertek Instruments Inc., Huntsville, AL).
For 37 case patients with nonmucinous ovarian cancers and for 100 control subjects (about 70% of all subjects), a CA 125 level had been determined previously (from the same specimens) and was available in our database for a comparison standard. These measurements had been performed with the original CA 125 radioimmunoassay from Centocor (Malvern, PA), and the assays were not repeated for this study.
Statistical Analysis
Univariate comparisons for quantitative variables between normal and cancer cell lines or between case and control sera were made by using Student's t test. For the analysis of serum levels, adjustment for potential confounding variables, such as the subject's age, year of collection, and whether the specimen had undergone freezing and thawing, was carried out by using general linear modeling. Logistic regression analysis was used to determine the statistical significance of both prostasin and CA 125 as a predictor of case status. Paired Student's t test was used to compare the change in postoperative prostasin levels from preoperative levels. Pearson correlation coefficients were calculated between CA 125 and prostasin. Because the distributions of prostasin and CA 125 were skewed positively, log-transformed values were used in the statistical tests. All of the analyses were performed with the Statistical Analyses System (SAS Institute, Cary, NC) or Splus (Insightful Corporation, Seattle, WA). Analyses with a P value of .05 or less were considered to be statistically significant. All statistical tests were two-sided, and all confidence intervals (CIs) are 95%. Fig. 1 shows a selected portion of the microarray analysis of pooled RNA isolated from three normal HOSE cell lines (labeled with the fluorescent dye Cy5) and from three ovarian cancer cell lines (labeled with the fluorescent dye Cy3). Thirty genes with Cy3/Cy5 signal ratios ranging from 5 to 444 were identified, suggesting that these genes were overexpressed in ovarian cancer cells compared with normal HOSE cells, and have been described previously (12) . Among them, both prostasin and osteopontin encode secretory proteins, which may be potential serum markers. Another gene, creatine kinase B, has been shown to produce a serum marker associated with renal carcinoma and lung cancer (13, 14) . We selected the prostasin gene, with a Cy3/Cy5 ratio of 170, for further study because this gene had an available antibody assay.
RESULTS
To evaluate the differential expression of prostasin in individual normal and malignant ovarian epithelial cell lines from normal and neoplastic ovaries, we performed quantitative PCR analysis on four normal HOSE cultures and on 10 ovarian cancer cell lines (Table 1) . The 2 −⌬⌬C T value, which represents relative prostasin gene expression, ranged from 120.3-fold to 410.1-fold greater for seven of the 10 ovarian cancer cell lines compared with that for HOSE697 cells, but it was only marginally greater for the other three ovarian cancer cell lines (ALST, DOV13, and SKOV3). Overall, there was a highly statistically significant difference between the mean 2 −⌬⌬C T values for the four normal cell lines compared with those for the 10 ovarian cancer lines (P<.001).
For further validation of the expression of prostasin in actual tumor tissue, sections from two normal ovaries, from two serous borderline ovarian tumors, and from two grade 1, two grade 2, and two grade 3 serous ovarian cystadenocarcinomas were immunostained with an anti-prostasin polyclonal antibody. Stronger cytoplasmic staining was detected in cancer cells than in normal HOSE cells, suggesting that prostasin is overexpressed by the ovarian cancer cells (Fig. 2) . Prostasin was, however, also detected in normal ovarian tissue by immunostaining.
We next examined prostasin levels detected by ELISA in sera from case patients and control subjects ( Table 2 ). The mean (and 95% CI) prostasin level for all of the case patients was 13.7 g/mL (95% CI ‫ס‬ 10.5 to 16.9 g/mL) compared with 7.5 g/mL (95% CI ‫ס‬ 6.6 to 8.3 g/mL) in all of the control subjects. Based on log-transformed values, this difference was statistically significant (P<.001) and persisted after adjustment for the subject's age, year of collection, and quality of specimen (possible freeze-thaw damage). Among case patients, there was considerable variability by stage; however, notably, women with stage II disease had the highest level of prostasin, suggesting that M33011,  J04765, L41351, L19783, U96759, M57730, L33930, D55672,  U97188, L19871, J04991, D00762, U17989, U43148,  AF010312, M80244, X99802, U05598, L47647, M55284,  X15722, S54005, AB006965, M83653, X12597, M18112,  U56816, X06233, D85181, and M31627. prostasin may be of use for early-stage detection. It also appeared that women with mucinous-type ovarian tumors had lower levels of prostasin than women with ovarian tumors of other epithelial types. Among control subjects, there was a statistically significant tendency for the archived specimens to have lower prostasin levels than the current specimens (P<.001), but there was no evidence for an effect of age or diagnostic category (i.e., normal tissue, benign gynecologic disease, or other gynecologic cancer). In addition, 60.5% of the archived case specimens and 66.2% of the control specimens had been in the freezer in which freezing and thawing had occurred. There was no evidence of a tendency for these samples to have lower prostasin levels ( Table 2 ). Fig. 3 shows a box plot of serum prostasin level for case patients with nonmucinous ovarian cancers and for the various control subgroups. Concerning the two control subjects with benign gynecologic disease, who were outliers in Fig. 3 , one had uterine fibroid tumors and the other had an extensive family history of ovarian cancer and had been referred to a gynecologic oncologist because pelvic washings at laparoscopy contained "suspicious" mesothelial cells. She was found to have extensive endosalpingiosis at prophylactic oophorectomy.
In 16 women with nonmucinous epithelial ovarian cancers, preoperative and postoperative specimens were available for comparison (Fig. 4) . For 14 of these women, a decreased prostasin level was observed after surgery, and, in the entire group of 16, postoperative P levels were statistically significantly lower compared with preoperative levels with the use of a paired t test on the log-transformed values (P ‫ס‬ .004). Fig. 5 displays a bivariate plot of prostasin versus CA 125 for the 37 case patients with nonmucinous ovarian cancers and for the 100 control subjects who had both measurements available. For the case patients with nonmucinous cancers, the correlation was .217 (P ‫ס‬ .20). For the control subjects, the correlation was -.004 (P ‫ס‬ .97). This lack of correlation suggests that the two may provide complementary information. Indeed, as shown by the curved line in Fig. 5 illustrating the separation that can be obtained between case patients and control subjects with both variables, the combined markers achieved a sensitivity of 34/37 ‫ס‬ 92% (95% CI ‫ס‬ 78.1% to 98.3%) and a specificity of 94/100 ‫ס‬ 94% (95% CI ‫ס‬ 87.4% to 97.7%). In contrast, the sensitivity of CA 125 alone at the same specificity was 24/37 ‫ס‬ 64.9% (95% CI ‫ס‬ 47.5% to 79.8%), and the sensitivity of prostasin alone at the same specificity was 19/37 ‫ס‬ 51.4% (95% CI ‫ס‬ 34.4% to 68.1%).
DISCUSSION
Using microarray technology on RNA pooled from ovarian cancer and the HOSE cell line, we have identified an overexpressed gene that produces a secretory product, prostasin. We have demonstrated prostasin's potential as a biomarker through real-time PCR in cancer and normal epithelial cell lines and by differential staining in cancer tissue compared with normal tissue. Finally, we demonstrated higher levels of serum prostasin in case patients with ovarian cancer than in control subjects and declining levels of prostasin after surgery for ovarian cancer. Prostasin was isolated originally from human seminal fluid and is present at the highest level in the prostate gland (10) . Immunohistochemical studies (15) have demonstrated that prostasin is localized in the epithelial cells and ducts of the prostate gland, and it is postulated that prostasin is synthesized in prostatic epithelial cells, secreted into the ducts, and finally excreted into the seminal fluid. The high levels of prostasin found in the prostate gland and in seminal fluid suggest that it may perform important physiologic functions during fertilization, such as liquefaction of semen or activation of other proteinases such as acrosin. Prostasin is also expressed at much lower levels in a variety of human tissues, including kidney, liver, pancreas, salivary gland, lung, bronchus, and colon, but its functions in these *CI ‫ס‬ confidence interval; GYN ‫ס‬ gynecologic. †Of the archived specimens, 23 (60.5%) of 38 case specimens were subjected to freezing and thawing compared with 57 (66.3%) of 86 control specimens. The mean value for case specimens with a freeze-thaw episode was 14.4 g/mL compared with 7.9 g/mL without. The mean value for control specimens with a freeze-thaw episode was 6.5 g/mL compared with 6.3 g/mL without.
‡Stage I disease is confined to the ovaries; stage II is confined to the pelvis; stage III has spread to the bowel, omentum, or abdominal peritoneum; and stage IV involves distant metastases including liver parenchyma. Fig. 3 . Box plots of log-transformed prostasin levels in case patients with nonmucinous ovarian cancer and control subject subgroups. The box is bounded above and below by the 25% and 75% percentiles, the median is the line in the box, and the upper and lower error bars indicate about 99% of values. GYN ‫ס‬ gynecologic cases. tissues have not yet been determined (15) . Curiously, prostasin has not been detected in the testis or ovary.
Chemically, prostasin is a trypsin-like serine proteinase with an apparent molecular mass of 40 kd (11) . The 20-amino acid sequence at the amino terminus of prostasin is 50%-55% identical to that of human ␣-tryptase, elastase 2A and 2B, chymotrypsin, acrosin, and the catalytic chains of hepsin, plasma kallikrein, and coagulation factor XI (11) . Like the enzymatic activity of other serine proteinases, the enzymatic activity of prostasin is dependent on a catalytic triad of the amino acids histidine, aspartic acid, and serine (15) , which are present in motifs that are highly conserved among serine proteinases (16) . Similar to acrosin and testisin (17, 18) , prostasin is likely to be a membrane-anchored protein because there is a putative transmembrane domain of 19 amino acids at the carboxyl terminus that is believed to anchor the protein to the plasma membrane of prostate epithelial cells, from which it is released by cleavage. In view of prostasin's homology with other serine proteases, it is not surprising that several serine proteases are elevated in patients with ovarian cancer; these proteases include certain kallikreins such as protease M/kallikrein 6 (19) , prostate-specific antigen (20) , hepsin (21) , and testisin (18) . Our current understanding of prostasin does not provide an explanation of why it or other serine proteinases might be overexpressed in ovarian cancer.
Although we believe that we have demonstrated prostasin's potential value as a biomarker for ovarian cancer, this study has several potential limitations. First, our sample size is relatively small and not ideal for demonstrating the value of prostasin as a screening marker. Although all blood samples were drawn preoperatively, all of the women with ovarian cancer had symptomatic disease and about 55% had stage III disease or greater. 
Fig. 5.
Correlation between prostasin and CA 125 (on logarithmic scales) in case patients with nonmucinous ovarian tumors and in control subjects. Curve illustrates the separation that can be achieved between case patients and control subjects by a logistic model using both CA 125 and prostasin levels.
In addition, a majority of the sera were obtained from an archived bank, and some of the specimens had undergone freezing and thawing. We observed no tendency for freezing and thawing to produce lower prostasin levels; however, there was evidence that specimens kept in the freezer longer may have had lower values for prostasin. For this reason, we adjusted for length of freezer storage in the multivariate model, and this adjustment did not negate the difference between case patients with ovarian cancer and control subjects. Our sample did not address prostasin's potential as a marker for tumor recurrence because sera preceding recurrences were not available. Finally, we can only partially address how prostasin might be complementary to other markers for ovarian cancer. It may be complementary to CA 125 as suggested by the low correlation between the two.
We believe that our study also demonstrates the potential value of microarray technology to identify tumor biomarkers that may have clinical usefulness. In this study, we used the MICROMAX cDNA microarray system that contained the 2400 genes with known function at the time of the development of this chip (13) . We selected this chip because it was the only chip available at the time that we began this research. Subsequently, microarrays with an even larger collection of genes or expression-sequencing tags have become available, such as the GeneChip™ U95 Set (Affymetrix Inc., Santa Clara, CA) and the GeneAlbum™ GEM™ 1-6 (IncyteGenomics, San Francisco, CA), which represent more than 50 000 genes or expressionsequencing tags. Besides choice of the microarray chip, an important technical issue is the source of the tumor and the normal cDNA for comparison. In this study, we pooled cDNA from several cancer cell lines and compared it with cDNA from normal HOSE cells. The principal advantage of using cell lines is that they provide an abundant source of RNA from the precise cell types involved in epithelial ovarian cancer. Their chief disadvantage is that they are a step removed from the actual cancer in vivo and would not detect genes that might be differentially expressed in the stroma of ovarian cancer specimens and that might be important.
Our study also provides a case illustration of the types of validation studies, which are necessary once a differentially expressed gene has been identified through microarray technology. Overexpression of a gene should be confirmed in individual cell lines or in tissues from individuals with cancer or from normal control subjects. Under ideal circumstances, an assay will be available to detect the gene product through either immunostaining of tissues or detection in sera. At each step, these validation studies must be consistent with differential expression associated with the cancer. Thus, although our preliminary study described 30 genes overexpressed in ovarian cancer cell lines when we used the MICROMAX cDNA microarray system (13), we have focused on one of the candidate genes in this study, which we believe has satisfied these additional elements of validation.
In conclusion, we believe that our study demonstrates the potential value of the powerful new technology of cDNA microarray in identifying overexpressed genes in ovarian cancer, and we suggest that prostasin may be a biomarker with clinical potential. Thus, larger studies that can yield more precise estimates of the sensitivity and specificity of prostasin, either alone or in combination with CA 125, will be necessary.
